GMAB (Genmab A/S) Earnings growth in current year

Official company branding of genmab.com (GMAB)

Genmab A/S dominates the targeted oncology niche thanks to its exclusive antibody platform. The annual variable EPS illustrates the earnings per share trend, where the value -19.60 shows the current figure. The company leverages its patent moat to create breakthrough drugs and subsequently transfer rights to Big Pharma. This monetization strategy transforms scientific achievements into a steady stream of high-margin royalties.

GMAB (Genmab) Earnings growth in current year history from 07/04/2022 to 11/10/2026

Comprehensive metric breakdowns and analytics for Genmab A/S (GMAB)

- share price and expert price forecast:
Price Genmab AS|GMAB - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Genmab Corp|GMAB - Total Company Value
- book capitalization data:
Accounting Value of a Share Genmab|GMAB - Book Capitalization|Market Value to Equity Ratio genmab.com|GMAB - Company Total Assets
- debt and liquidity details:
Debt to Capital Genmab A/S|GMAB - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio genmab.com|GMAB - Company Aggregate Debts|Debts to Book Value Genmab Corp|GMAB - Company Long-Term Debts|Company Short-Term Indebtedness Genmab|Intermediate Coverage Ratio genmab.com
- net income and valuation multiples indicators:
GMAB - Net Income|Future Net Profit Genmab A/S|GMAB - P/E Multiple|Future Price to Earnings Multiple Genmab Corp|GMAB - PEG Multiple|Company Value to EBITDA Genmab Corp|GMAB - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Genmab|GMAB - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth genmab.com|GMAB - Earnings per share growth in current year|Net earnings per share change forecast for next year Genmab A/S
Fundamental valuation:GMAB Genmab AS
Signature product of Genmab Corp

For Genmab A/S, the year-over-year relative change in EPS reflects the effectiveness of its strategy to evolve into a biotech behemoth by capitalizing on licensing royalties. This indicator measures the growth rate of net income per share, allowing investors to assess the real-time monetization of innovations and the fundamental resilience of the business regardless of market volatility.

Direct competitors

EXEL: Net earnings per one share growth for the current year|NUVL (Nuvalent Corp) - Earnings growth in current year|Earnings growth in current year Kymera Corp|Earnings per share growth in current year IDEAYA Biosciences (IDYA)|ELVN (enliventherapeutics.com) - Earnings per share increase in current year|Earnings growth in current year ORIC (ORIC Pharmaceuticals, Inc.)|Net earnings per share change in current year Relay Therapeutics Inc|Nurix Pharma - Earnings growth in current year|Earnings per share growth rate in current year Tyra Corp|VSTM (Verastem, Inc.) - Net earnings per share growth this year|GLUE: Net earnings per one share growth for the current year|CGEM (Cullinan Therapeutics, Inc.) - Earnings growth in current year|Earnings per share growth rate in current year Immuneering Corp IMRX|Earnings growth in current year CCCC|Black Diamond Therapeutics, Inc - Earnings per share growth this year|Repare Therapeutics - Net earnings per share growth this year|Earnings per share increase in current year PMVP|KPTI: Net earnings per share growth this year|Propanc Biopharma Inc - Net earnings per one share growth for the current year|BGMS: Earnings growth in current year|Aadi Bioscience, Inc. - Earnings per share increase in current year|ALRN (Aileron Therapeutics Inc) - Earnings growth in current year|Earnings per share growth rate in current year Blueprint Medicines Corp BPMC|Earnings per share growth in current year GlycoMimetics, Inc. (GLYC)|SWTX (SpringWorks Therapeutics Inc.) - Earnings per share increase in current year